Malignant peripheral nerve sheath tumor
MONDO:0017827Malignant peripheral nerve sheath tumor (MPNST) is a rare and often aggressive soft tissue sarcoma occurring in a wide range of anatomical sites.
Also known as: neurofibrosarcoma, MPNST, Malig. periph. nerve sheath tum., malignant neoplasm of peripheral nerve sheath, malignant neurilemmoma, malignant neurilemoma, malignant neurofibroma, malignant peripheral nerve sheath neoplasm
2936 clinical trials for this condition and its sub-types, 36 tagged with Malignant peripheral nerve sheath tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Malignant peripheral nerve sheath tumor
-
Childhood malignant schwannoma 1 trial
-
Malignant triton tumor 1 trial
-
Adult malignant schwannoma 0 trials
-
Immunotherapy duo tackles rare nerve cancer in early trial
Disease control CompletedThis early-phase trial tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) before standard surgery, chemotherapy, or radiation is safe and feasible for people with Neurofibromatosis Type 1 who have a rare malignant peripheral nerve sheath tumor. Only 13 parti…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for rare nerve tumors
Disease control CompletedThis phase 2 trial tested two drugs, selumetinib and sirolimus, in 21 people with advanced malignant peripheral nerve sheath tumors (MPNST), a rare cancer often linked to neurofibromatosis type 1. The goal was to see if the combination could shrink or stabilize tumors. The study …
Phase 2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control CompletedThis study tested a combination of two drugs, cobimetinib and atezolizumab, in children and adults with advanced soft tissue sarcoma that has spread. The goal was to see if the combo is safe and can stop tumors from growing. About 229 people took part, and researchers measured ho…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Personalized chemo shows promise against rare sarcomas
Disease control CompletedThis Phase 3 trial tested whether giving chemotherapy based on the specific type of soft tissue sarcoma works better than a one-size-fits-all approach. 550 adults with high-risk sarcomas in the arms or trunk were randomly assigned to standard chemo or a chemo regimen matched to t…
Phase 3 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New scan and genetic tests aim to catch cancer early in NF1 patients
Knowledge-focused CompletedThis study looked at people with neurofibromatosis type 1 (NF1) to better understand how harmless tumors (plexiform neurofibromas) turn into a rare cancer called MPNST. Ten participants had MRI, PET scans, and tumor biopsies. Researchers tested whether a special PET scan (FLT PET…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC